エルラナタマブ (遺伝子組換え) (JAN);
Elranatamab (USAN);
Elranatamab (genetical recombination) (JAN);
Elranatamab-bcmm

ELREXFIO (Pfizer Laboratories Div Pfizer), ELREXFIO (U.S. Pharmaceuticals)

C6440H9958N1738O2010S49

145369.6742

145459.69

(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYYMTWVRQA PGKGLEWVAF IRNRARGYTS
DHNPSVKGRF TISRDNAKNS LYLQMNSLRA EDTAVYYCAR DRPSYYVLDY WGQGTTVTVS
SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSNFGTQ TYTCNVDHKP SNTKVDKTVE RKCRVRCPRC PAPPVAGPSV
FLFPPKPKDT LMISRTPEVT CVVVAVSHED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF
RVVSVLTVVH QDWLNGKEYK CKVSNKGLPS SIEKTISKTK GQPREPQVYT LPPSREEMTK
NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLDS DGSFFLYSRL TVDKSRWQQG
NVFSCSVMHE ALHNHYTQKS LSLSPGK
(heavy chain)
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYPMSWVRQA PGKGLEWVSA IGGSGGSLPY
ADIVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARYW PMDIWGQGTL VTVSSASTKG
PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL
SSVVTVPSSN FGTQTYTCNV DHKPSNTKVD KTVERKCEVE CPECPAPPVA GPSVFLFPPK
PKDTLMISRT PEVTCVVVAV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTFRVVSVL
TVVHQDWLNG KEYKCKVSNK GLPSSIEKTI SKTKGQPREP QVYTLPPSRE EMTKNQVSLT
CEVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL YSKLTVDKSR WQQGNVFSCS
VMHEALHNHY TQKSLSLSPG K
(Light chain)
DIVMTQSPDS LAVSLGERAT INCKSSQSLF NVRSRKNYLA WYQQKPGQPP KLLISWASTR
ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCKQSYDL FTFGSGTKLE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(light chain)
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLMY DASIRATGIP
DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYQSWPLTFG QGTKVEIKRT VAAPSVFIFP
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
(Disulfide bridge: H22-H98, H135-L219, H148-H204, H223-h217, H227-h221, H230-h224, H261-H321, H367-H425, h22-h96, h129-l215, h142-h198, h255-h315, h361-h419, L23-L94, L139-L199, l23-l89, l135-l195)

抗悪性腫瘍薬

CD3E [HSA:916] [KO:K06451]

DDI search